391 related articles for article (PubMed ID: 23994885)
1. Antitumor impact of interferon-γ producing CD1d-restricted NKT cells in murine malignant mesothelioma.
Tagawa T; Wu L; Anraku M; Yun Z; Rey-McIntyre K; de Perrot M
J Immunother; 2013 Oct; 36(8):391-9. PubMed ID: 23994885
[TBL] [Abstract][Full Text] [Related]
2. Administration of anti-CD25 mAb leads to impaired α-galactosylceramide-mediated induction of IFN-γ production in a murine model.
Rosalia RA; Štěpánek I; Polláková V; Šímová J; Bieblová J; Indrová M; Moravcová S; Přibylová H; Bontkes HJ; Bubeník J; Sparwasser T; Reiniš M
Immunobiology; 2013 Jun; 218(6):851-9. PubMed ID: 23182710
[TBL] [Abstract][Full Text] [Related]
3. Promotion or Suppression of Murine Intestinal Polyp Development by iNKT Cell Directed Immunotherapy.
Wang Y; Sedimbi SK; Löfbom L; Besra GS; Porcelli SA; Cardell SL
Front Immunol; 2019; 10():352. PubMed ID: 30881361
[TBL] [Abstract][Full Text] [Related]
4. Increased frequency of circulating invariant natural killer T cells in malignant pleural mesothelioma patients.
Altomare E; Fallarini S; Biaggi G; Gattoni E; Botta M; Lombardi G
Cancer Biol Ther; 2012 Jul; 13(9):702-11. PubMed ID: 22684580
[TBL] [Abstract][Full Text] [Related]
5. Activation of CD1d-restricted natural killer T cells can inhibit cancer cell proliferation during chemotherapy by promoting the immune responses in murine mesothelioma.
Wu L; Yun Z; Tagawa T; De la Maza L; Wu MO; Yu J; Zhao Y; de Perrot M
Cancer Immunol Immunother; 2014 Dec; 63(12):1285-96. PubMed ID: 25183171
[TBL] [Abstract][Full Text] [Related]
6. Synergistic antitumor effects of regulatory T cell blockade combined with pemetrexed in murine malignant mesothelioma.
Anraku M; Tagawa T; Wu L; Yun Z; Keshavjee S; Zhang L; Johnston MR; de Perrot M
J Immunol; 2010 Jul; 185(2):956-66. PubMed ID: 20548032
[TBL] [Abstract][Full Text] [Related]
7. NKT cells enhance CD4+ and CD8+ T cell responses to soluble antigen in vivo through direct interaction with dendritic cells.
Hermans IF; Silk JD; Gileadi U; Salio M; Mathew B; Ritter G; Schmidt R; Harris AL; Old L; Cerundolo V
J Immunol; 2003 Nov; 171(10):5140-7. PubMed ID: 14607913
[TBL] [Abstract][Full Text] [Related]
8. The development of airway hyperreactivity in T-bet-deficient mice requires CD1d-restricted NKT cells.
Kim HY; Pichavant M; Matangkasombut P; Koh YI; Savage PB; DeKruyff RH; Umetsu DT
J Immunol; 2009 Mar; 182(5):3252-61. PubMed ID: 19234223
[TBL] [Abstract][Full Text] [Related]
9. Activation of invariant NKT cells confers protection against Chlamydia trachomatis-induced arthritis.
Bharhani MS; Chiu B; Na KS; Inman RD
Int Immunol; 2009 Jul; 21(7):859-70. PubMed ID: 19477915
[TBL] [Abstract][Full Text] [Related]
10. Combination of NKT14m and Low Dose IL-12 Promotes Invariant Natural Killer T Cell IFN-γ Production and Tumor Control.
Guan P; Schaub R; Nichols KE; Das R
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32708464
[TBL] [Abstract][Full Text] [Related]
11. iNKT cells suppress the CD8+ T cell response to a murine Burkitt's-like B cell lymphoma.
Bjordahl RL; Gapin L; Marrack P; Refaeli Y
PLoS One; 2012; 7(8):e42635. PubMed ID: 22880059
[TBL] [Abstract][Full Text] [Related]
12. Activation of human invariant natural killer T cells with a thioglycoside analogue of α-galactosylceramide.
Hogan AE; O'Reilly V; Dunne MR; Dere RT; Zeng SG; O'Brien C; Amu S; Fallon PG; Exley MA; O'Farrelly C; Zhu X; Doherty DG
Clin Immunol; 2011 Aug; 140(2):196-207. PubMed ID: 21493160
[TBL] [Abstract][Full Text] [Related]
13. Invariant NKT cells facilitate cytotoxic T-cell activation via direct recognition of CD1d on T cells.
Qin Y; Oh S; Lim S; Shin JH; Yoon MS; Park SH
Exp Mol Med; 2019 Oct; 51(10):1-9. PubMed ID: 31653827
[TBL] [Abstract][Full Text] [Related]
14. CD1d-independent activation of mouse and human iNKT cells by bacterial superantigens.
Hayworth JL; Mazzuca DM; Maleki Vareki S; Welch I; McCormick JK; Haeryfar SM
Immunol Cell Biol; 2012 Aug; 90(7):699-709. PubMed ID: 22041925
[TBL] [Abstract][Full Text] [Related]
15. Natural killer T cell activation increases iNOS
Paul S; Chhatar S; Mishra A; Lal G
J Immunother Cancer; 2019 Aug; 7(1):208. PubMed ID: 31387637
[TBL] [Abstract][Full Text] [Related]
16. Targeted delivery of α-galactosylceramide to CD8α+ dendritic cells optimizes type I NKT cell-based antitumor responses.
Macho-Fernandez E; Cruz LJ; Ghinnagow R; Fontaine J; Bialecki E; Frisch B; Trottein F; Faveeuw C
J Immunol; 2014 Jul; 193(2):961-9. PubMed ID: 24913977
[TBL] [Abstract][Full Text] [Related]
17. Preclinical evaluation of invariant natural killer T cells in the 5T33 multiple myeloma model.
Nur H; Fostier K; Aspeslagh S; Renmans W; Bertrand E; Leleu X; Favreau M; Breckpot K; Schots R; De Waele M; Van Valckenborgh E; De Bruyne E; Facon T; Elewaut D; Vanderkerken K; Menu E
PLoS One; 2013; 8(5):e65075. PubMed ID: 23741460
[TBL] [Abstract][Full Text] [Related]
18. Dendritic cell internalization of α-galactosylceramide from CD8 T cells induces potent antitumor CD8 T-cell responses.
Choi DH; Kim KS; Yang SH; Chung DH; Song B; Sprent J; Cho JH; Sung YC
Cancer Res; 2011 Dec; 71(24):7442-51. PubMed ID: 22028323
[TBL] [Abstract][Full Text] [Related]
19. Characterizing porcine invariant natural killer T cells: A comparative study with NK cells and T cells.
Yang G; Artiaga BL; Lewis ST; Driver JP
Dev Comp Immunol; 2017 Nov; 76():343-351. PubMed ID: 28694168
[TBL] [Abstract][Full Text] [Related]
20. Invariant NKT cells suppress CD8(+) T-cell-mediated allergic contact dermatitis independently of regulatory CD4(+) T cells.
Goubier A; Vocanson M; Macari C; Poyet G; Herbelin A; Nicolas JF; Dubois B; Kaiserlian D
J Invest Dermatol; 2013 Apr; 133(4):980-7. PubMed ID: 23190881
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
